SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Carlsson Bengt)
 

Search: WFRF:(Carlsson Bengt) > Unfolding a folding...

Unfolding a folding disease: folding, misfolding and aggregation of the marble brain syndrome-associated mutant H107Y of human carbonic anhydrase II

Almstedt, Karin, 1980- (author)
Linköpings universitet,Biokemi,Tekniska högskolan
Lundqvist, Martin (author)
Linköpings universitet,Molekylär Bioteknik,Tekniska högskolan
Carlsson, Jonas (author)
Linköpings universitet,Bioinformatik,Tekniska högskolan
show more...
Karlsson, Martin (author)
Linköpings universitet,Biokemi,Tekniska högskolan
Persson, Bengt (author)
Linköpings universitet,Bioinformatik,Tekniska högskolan
Jonsson, Bengt-Harald (author)
Linköpings universitet,Molekylär Bioteknik,Tekniska högskolan
Carlsson, Uno (author)
Linköpings universitet,Biokemi,Tekniska högskolan
Hammarström, Per (author)
Linköpings universitet,Biokemi,Tekniska högskolan
show less...
 (creator_code:org_t)
Oxford : Elsevier, 2004
2004
English.
In: Journal of Molecular Biology. - Oxford : Elsevier. - 0022-2836 .- 1089-8638. ; 342:2, s. 619-633
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Most loss-of-function diseases are caused by aberrant folding of important proteins. These proteins often misfold due to mutations. The disease marble brain syndrome (MBS), known also as carbonic anhydrase II deficiency syndrome (CADS), can manifest in carriers of point mutations in the human carbonic anhydrase II (HCA II) gene. One mutation associated with MBS entails the His107Tyr substitution. Here, we demonstrate that this mutation is a remarkably destabilizing folding mutation. The loss-of-function is clearly a folding defect, since the mutant shows 64% of CO2 hydration activity compared to that of the wild-type at low temperature where the mutant is folded. On the contrary, its stability towards thermal and guanidine hydrochloride (GuHCl) denaturation is highly compromised. Using activity assays, CD, fluorescence, NMR, cross-linking, aggregation measurements and molecular modeling, we have mapped the properties of this remarkable mutant. Loss of enzymatic activity had a midpoint temperature of denaturation (Tm) of 16 °C for the mutant compared to 55 °C for the wild-type protein. GuHCl-denaturation (at 4 °C) showed that the native state of the mutant was destabilized by 9.2 kcal/mol. The mutant unfolds through at least two equilibrium intermediates; one novel intermediate that we have termed the molten globule light state and, after further denaturation, the classical molten globule state is populated. Under physiological conditions (neutral pH; 37 °C), the His107Tyr mutant will populate the molten globule light state, likely due to novel interactions between Tyr107 and the surroundings of the critical residue Ser29 that destabilize the native conformation. This intermediate binds the hydrophobic dye 8-anilino-1-naphthalene sulfonic acid (ANS) but not as strong as the molten globule state, and near-UV CD reveals the presence of significant tertiary structure. Notably, this intermediate is not as prone to aggregation as the classical molten globule. As a proof of concept for an intervention strategy with small molecules, we showed that binding of the CA inhibitor acetazolamide increases the stability of the native state of the mutant by 2.9 kcal/mol in accordance with its strong affinity. Acetazolamide shifts the Tm to 34 °C that protects from misfolding and will enable a substantial fraction of the enzyme pool to survive physiological conditions.

Subject headings

NATURVETENSKAP  -- Biologi -- Biokemi och molekylärbiologi (hsv//swe)
NATURAL SCIENCES  -- Biological Sciences -- Biochemistry and Molecular Biology (hsv//eng)

Keyword

Misfolding
loss-of-function
aggregation
molten globule
misfolding inhibitor
Biochemistry
Biokemi

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view